CASPASE-7 DEVDGK

CASPASE-7 DEVDGK

• 批准号: 8363369
• 负责人: Jeanne Ann Hardy
• 金额: $ 0.25万
• 依托单位: BROOKHAVEN SCIENCE ASSOC-BROOKHAVEN LAB
• 依托单位国家: 美国
• 财政年份: 2011
• 资助国家: 美国
• 起止时间: 2011-07-01 至 2012-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8363369
• 关键词: Adverse effects; Alzheimer' s Disease; Antineoplastic Agents; Caspase; Cell Death; Crystallography; Disease Progression; Funding; Grant; Huntington Disease; Light; Molecular; Molecular Conformation; National Center for Research Resources; Nerve Degeneration; Parkinson Disease; Peptide Hydrolases; Pharmaceutical Preparations; Principal Investigator; Regulation; Research; Research Infrastructure; Resources; Source; Structure; Synchrotrons; United States National Institutes of Health; caspase-7; cost; inhibitor/antagonist

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. Primary support for the subproject and the subproject's principal investigator may have been provided by other sources, including other NIH sources. The Total Cost listed for the subproject likely represents the estimated amount of Center infrastructure utilized by the subproject, not direct funding provided by the NCRR grant to the subproject or subproject staff. Caspases are proteases involved in regulating cell death appropriately. As a result caspases are targets for both cancer drugs (anti-proliferative drugs) and neurodegeneration, since caspases are involved in disease progression in Huntington's, Alzheimer's and Parkinson's Diseases. Our project allows us to determine the structure of caspase-7 with a new class of inhibitors that may be provide caspase regulation with fewer side effects. In addition our structure will be the first to show the "active" conformation of the catalytic diad, and is thus poised to shed light on the molecular details of caspase function.

这个子项目是许多利用资源的研究子项目之一 由NIH/NCRR资助的中心拨款提供。子项目的主要支持 而子项目的主要调查员可能是由其他来源提供的， 包括其它NIH来源。 列出的子项目总成本可能 代表子项目使用的中心基础设施的估计数量， 而不是由NCRR赠款提供给子项目或子项目工作人员的直接资金。 半胱天冬酶是参与适当调节细胞死亡的蛋白酶。因此，半胱天冬酶是癌症药物（抗增殖药物）和神经变性的靶标，因为半胱天冬酶参与亨廷顿病、阿尔茨海默病和帕金森病的疾病进展。我们的项目使我们能够用一类新的抑制剂来确定caspase-7的结构，这类抑制剂可能会提供caspase调节，副作用更少。此外，我们的结构将是第一个显示催化二联体的“活性”构象，因此有望揭示半胱天冬酶功能的分子细节。